Jacob Linu Abraham, Begum Tarjina, Halder Arkoprovo, Babu M C Suresh, Lokesh K N, Rudresha A H, Rajeev L K, Saldanha Smitha C
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M. H. Marigowda Road, Bengaluru, Karnataka India.
Department of Medical Oncology, Medica Cancer Hospital, Rangapani, Siliguri, West Bengal India.
Indian J Hematol Blood Transfus. 2024 Jul;40(3):392-399. doi: 10.1007/s12288-024-01735-9. Epub 2024 Feb 9.
Hodgkin's lymphoma treatment outcomes have been the true success story of modern medicine. Various data from western as well as Indian studies are available for classical Hodgkin's lymphoma (cHL). Here we report treatment outcomes from a tertiary cancer care centre in Karnataka over a 5 year period. This was a retrospective review of cHL cases aged 15 years and above diagnosed between January 2015 and December 2019 at Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India. The case files of the patients were retrieved and relevant data was collected. Two hundred patients of cHL were included in this study. Median age was 28 years with male to female ratio of 1.56:1. B symptoms were present in 58% cases. Mixed cellularity (46.5%) was the most common histological subtype. Majority patients had advanced stage at presentation (stage III/IV) (62.5%). Extranodal disease was present in 19.5% cases. GHSG early-favourable cases were 15.5%, early-unfavourable cases were 22.0%, while 62.5% were advanced cases. The most common chemotherapy regimen used was ABVD. Eighty-three (41.5%) patients received radiation therapy. Median follow-up was 34.2 months (range 4.1-67.8). The rates for complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) were 84.5%, 8.5%, 5.0% and 2.0% respectively. PFS and OS rate at 6 years were 69.5% and 84.1% respectively. HL is one of the malignancies with high cure rate. The treatment outcome at our centre is comparable to western data and data from other tertiary centres from India.
霍奇金淋巴瘤的治疗成果堪称现代医学的成功典范。来自西方以及印度研究的各类数据涵盖了经典霍奇金淋巴瘤（cHL）。在此，我们报告印度卡纳塔克邦一家三级癌症护理中心5年期间的治疗成果。这是一项对2015年1月至2019年12月在印度卡纳塔克邦班加罗尔基德瓦伊纪念肿瘤研究所诊断出的15岁及以上cHL病例的回顾性研究。检索了患者的病历并收集了相关数据。本研究纳入了200例cHL患者。中位年龄为28岁，男女比例为1.56:1。58%的病例出现B症状。混合细胞型（46.5%）是最常见的组织学亚型。大多数患者初诊时处于晚期（III/IV期）（62.5%）。19.5%的病例存在结外病变。德国霍奇金淋巴瘤研究组（GHSG）早期预后良好的病例占15.5%，早期预后不良的病例占22.0%，而晚期病例占62.5%。最常用的化疗方案是ABVD。83例（41.5%）患者接受了放射治疗。中位随访时间为34.2个月（范围4.1 - 67.8个月）。完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）和疾病进展（PD）的发生率分别为84.5%、8.5%、5.0%和2.0%。6年时的无进展生存期（PFS）和总生存期（OS）率分别为69.5%和84.1%。HL是治愈率较高的恶性肿瘤之一。我们中心的治疗结果与西方数据以及印度其他三级中心的数据相当。
